СУРУНКАЛИ ЮРАК ЕТИШМОВЧИЛИГИДА БУЙРАКЛАР ДИСФУНКЦИЯСИ РИВОЖЛАНИШ МЕХАНИЗМЛАРИ ҲАМДА КАСАЛЛИК РИВОЖЛАНИШИДА СИЙДИК КИСЛОТАСИНИ ТУТГАН ЎРНИ
##article.subject##:
Сурункали юрак етишмовчилиги, буйраклар дисфункцияси, коморбид, кардиоренал синдром, сурункали буйрак касаллиги, гиперурикемия, Ренин-Ангиотензин-Алдостерон-Тизими, сийдик кислота##article.abstract##
Маълумки, юрак қон-томир касалликлари ва буйраклар дисфункцияси мустақил равишда ҳамда бири иккинчисининг негизида юзага келиши сифатида намоён бўлади. Ушбу мақолада сурункали юрак етишмовчилиги оқибатида буйраклар дисфункцияси ривожланиш механизмларини тушунтирувчи маълумотлар келтирилди. Юрак қон-томир тизми ва буйраклар ўртасидаги патологик жараёнларни боғлайдиган кардиоренал синдром ҳақидаги тадқиқотлар кўриб чиқилди. Шунингдек, сурункали юрак етишмовчилиги фонида буйраклар дисфункцияси ривожланишида сийдик кислотасининг аҳамиятини изоҳловчи илмий ишлар батафсил ёритилган.
Библиографические ссылки
Gadayev AG, Turakulov RI, Kurbonov AK, Rakhimova ME Role of Hepcidin and ProInflammatory Cytokines in Chronic Heart Failure in Combination with Anemia. Central Asian Journal of Medicine Central Asian Journal of Medicine 2019.
Kizer, J.R.; Bella, J.N.; Palmieri, V.; Liu, J.E.; Best, L.G.; Lee, E.T.; Roman, M.J.; Devereux, R.B. Left atrial diameter as an independent predictor of first clinical cardiovascular events in middle-aged and elderly adults: The strong heart study (shs). Am. Heart J. 2006, 151, 412–418.
Olechnowicz-Tietz, S.; Gluba, A.; Paradowska, A.; Banach, M.; Rysz, J. The risk of atherosclerosis in patients with chronic kidney disease. Int. Urol. Nephrol. 2013, 45, 1605–1612.
Eknoyan G, Lameire N, Eckardt K, et al. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2013; 3:5–14.
Damman K, Valente MA, Voors AA, et al. Renal impairment, worsening renal function, and outcome in patients with heart failure: An updated meta-analysis. Eur Heart J 2014; 35: 455–469.
Roger VL, Go AS, Lloyd-Jone DM, et al. Heart disease and stroke statistics—2011 update: A report from the American Heart Association. Circulation 2011; 123: e18–e209.
Ronco C., Haapio M., House A.A., Anavekar N., Bellomo R. Cardiorenal syndrome//J Am CollCardiol. -2008. -Vol. 52, №19. -P. 1527-1539.
Turaqulov R.I. Surunkali yurak yetishmovchiligi kamqonlik bilan kechganda AAF geni polimorfizmini eritropoetin bilan bog‘liqligini o‘rganish hamda tashxislash va davolashga differensial yondoshish.
Schefold JC, Filippatos G, Hasenfuss G, et al. Heart failure and kidney dysfunction: Epidemiology, mechanisms and management. Nat Rev Nephrol 2016; 12:610.
Tsuruya K and Eriguchi M Cardiorenal syndrome in chronic kidney disease. Curr Opin Nephrol Hypertens 2015; 24:154–162.
Graziani G, Pini D, Oldani S, et al. Renal dysfunction in acute congestive heart failure: A common problem for cardiologists and nephrologists. Heart Fail Rev 2014; 19:699–708.
Gladden JD, Chaanine AH and Redfield MM Heart failure with preserved ejection fraction. Ann Rev Med 2018; 69:65–79.
Levin A, Stevens PE, Bilous RW, et al. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int Suppl 2013; 3:1–150.
Nimmo AJ, Than N, Orchard CH, et al. The effect of acidosis on beta-adrenergic receptors in ferret cardiac muscle. Exp Physiol 1993; 78:95–103.
Floras JS Sympathetic nervous system activation in human heart failure: Clinical implications of an updated model. J Am Coll Cardiol 2009; 54:375–385.
Parati G, Esler M The human sympathetic nervous system: Its relevance in hypertension and heart failure. Eur Heart J 2012; 33:1058–1066.
Lymperopoulos A, Rengo G, Koch WJ Adrenergic nervous system in heart failure: Pathophysiology and therapy. Circ Res 2013; 113:739–753.
Notarius CF, Millar PJ, Murai H, et al. Inverse relationship between muscle sympathetic activity during exercise and peak oxygen uptake in subjects with and without heart failure. J Am Coll Cardiol 2014; 63:605–606.
Middlekauff HR Making the case for skeletal myopathy as the major limitation of exercise capacity in heart failure. Circ Heart Fail 2010; 3:537–546.
Brum PC, Bacurau AVN, Medeiros A, et al. Aerobic exercise training in heart failure: Impact on sympathetic hyperactivity and cardiac and skeletal muscle function. Braz J Med Biol Res 2011; 44:827–835.
Sobotka PA, Mahfoud F, Schlaic MP, et al. Sympatho-renal axis in chronic disease. Clin Res Cardiol 2011; 100:1049–1057.
Grassi G Sympathetic neural activity in hypertension and related diseases. Am J Hypertens 2010; 23:1052–1060.
Grassi G, Quarti-Trevano F, Seravalle G, et al. Early sympathetic activation in the initial clinical stages of chronic renal failure.
Hypertension 2011; 57:846–851.
DiBona GF Physiology in perspective: The wisdom of the body. Neural control of the kidney. Am J Physiol Regul Integr Comp Physiol 2005; 289:R633–R641.
Zucker IH, Schultz HD, Patel KP, et al. Regulation of central angiotensin type 1 receptors and sympathetic outflow in heart failure. Am J Physiol Heart Circ Physiol 2009; 297:H1557–H1566.
Sata Y, Head GA, Denton K, et al. Role of the sympathetic nervous system and its modulation in renal hypertension. Front Med 2018; 5, 82.
Adams GR, Vaziri ND Skeletal muscle dysfunction in chronic renal failure: Effects of exercise. Am J Physiol Renal Physiol 2006; 290:F753–F761.
Okita K, Kinugawa S, Tsutsui H Exercise intolerance in chronic heart failure. Circ Journal 2013; 77:293–300.
Delafontaine P, Yoshida T The renin–angiotensin system and the biology of skeletal muscle: Mechanisms of muscle wasting in chronic disease states. Trans Am Clin Climatol Assoc 2016; 127:245–258.
Duan X, Ling F Is uric acid itself a player or a bystander in the pathophysiology of chronic heart failure? Med Hypotheses 2008; 70:578–581.
Ather S, Chan W, Bozkurt B, et al. Impact of noncardiac comorbidities on morbidity and mortality in a predominantly male population with heart failure and preserved versus reduced ejection fraction. J Am Coll Cardiol 2012; 59:998–1005.
Málek F, Ošťádal P, Pařenica J, et al. Uric acid, allopurinol therapy, and mortality in patients with acute heart failure—results of the Acute HEart FAilure Database registry. J Crit Care 2012; 27:737-e11.
Vaduganathan M, Greene SJ, Ambrosy AP, et al. Relation of serum uric acid levels and outcomes among patients hospitalized for worsening heart failure with reduced ejection fraction (from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan trial). Am J Cardiol 2014; 114:1713–1721.
Filippatos GS, Ahmed MI, Gladden JD, et al. Hyperuricaemia, chronic kidney disease, and outcomes in heart failure: Potential mechanistic insights from epidemiological data. Eur Heart J 2011; 32:712–720.
Baldasseroni S, Urso R, Maggioni AP, et al. .; IN-CHF Investigators. Prognostic significance of serum uric acid in outpatients with chronic heart failure is complex and related to body mass index: Data from the IN-CHF Registry. Nutr Metab Cardiovasc Dis 2012; 22:442–448.
Huang H, Huang B, Li Y, et al. Uric acid and risk of heart failure: A systematic review and meta-analysis. Eur J Heart Fail 2014; 16:15–24.
Mantovani A, Targher G, Temporelli PL, et al. Prognostic impact of elevated serum uric acid levels on long-term outcomes in patients with chronic heart failure: A post-hoc analysis of the GISSI-HF (Gruppo Italiano per lo Studio della Sopravvivenza nella Insufficienza Cardiaca-Heart Failure) trial. Metabolism 2018; 83:205–215.
Lippi G, Montagnana M, Franchini M, et al. The paradoxical relationship between serum uric acid and cardiovascular disease. Clin Chim Acta 2008; 392:1–7.
Desai RV, Ahmed MI, Fonarow GC, et al. 2010; Effect of serum insulin on the association between hyperuricemia and incident heart failure. Am J Cardiol 106:1134–1138.
